Deadline: 08-Aug-2025
Johnson & Johnson has launched the Korea Innovation QuickFire Challenge focused on Neuroscience. The challenge invites innovators from Korea and around the world who have a strong interest in engaging with the Korean innovation ecosystem.
Applicants are encouraged to submit solutions aimed at tackling difficult, hard-to-drug targets related to neurodegenerative diseases affecting the brain and eye, as well as neuropsychiatric disorders. The goal is to reduce the burden and impact of serious neurological conditions by advancing understanding and creating breakthrough treatments.
Selected innovators will be eligible to receive grant funding from a pool of up to $100,000, along with a one-year JLABS Korea membership and mentorship from Johnson & Johnson experts.
The challenge seeks novel chemical entities such as small molecules, peptides, RNA-targeting agents, molecular glues, or degraders. Submissions must show feasibility, proof of concept, and potential for therapeutic development to benefit individuals with conditions like Alzheimer’s disease, Parkinson’s disease, geographic atrophy, schizophrenia, major depressive disorder, and bipolar disorder.
Proposals will be assessed on their alignment with the challenge’s focus areas, potential to transform health outcomes, feasibility and data support, thoroughness, resource planning, and engagement with the Korean innovation ecosystem.
For more information, visit Johnson & Johnson.
